Frontage Holdings Corp. · HKEX:1521
Frontage — Investor Presentation (August 2019)
22 slides from Frontage's investor presentation, Aug 1, 2019

Slide 1: Corporate Overview: We Turn Services into Solutions
Corporate Overview We Turn Services into Solutions 1

Slide 2: History of Strong Growth
History of Strong Growth Over 18 Years of Excellence Concord Biosciences Preclinical and Sister CDMO, Agrochemical Frontida Acquired in Ohio Acquired Data Acquired in Strategic Management Philadelphia, PA 2018 and Biostats Investment Agreement Services 2016 Expanded & With Tigermed Acquired Phase I

Slide 3: Two Countries, One System
Two Countries, One System CHI Preclinical and Safety & Toxicology • Concord OH Bioanalytical Se Data Management • Shanghai, S and Biometrics • Princeton, NJ CMC Services • Suzhou Clinical operatio • Zhengzhou USA Hospital-Based Clinical Units • 18 co-developed clinical centers with more than 1,000 b

Slide 4: Our Strengths
Our Strengths Our Our Our Our Quality People Services Facilities Systems Strong Scientific and Broad and Integrated State of the Art Our Quality System; Management Product Development Equipment and “Two Countries, One Expertise Services Facilities System” Highly educated and Drug product Over $40 MM

Slide 5: Our Purpose, Vision and Values
Our Purpose, Vision and Values Our Purpose To improve quality of life Our Vision To be the preferred partner of life science leaders in product development Our Values Quality Integrity Innovation Caring We are committed to We believe in We employ new scientific We care for our patients, excellence i

Slide 6: Integrated, Analytical and Scientifically-Driven Research and Development Services
Integrated, Analytical and Scientifically-Driven Research and Development Services Our Services in Each Stage of The Drug Discovery and Development Process Pre-Clinical Clinical Trials Post Approval Drug Discovery Development (Phases I-III) (Phase IV) DMPK n PK screening and characterization n In vi

Slide 7: Highly experienced and professional management team
Highly experienced and professional management team Highly Experienced Senior Management Team Song Li, Ph.D. Zhihe Li, Ph.D., M.D. Hugh M. Davis, Joe (Yifeng) Gao Founder and CEO, Frontage Ph.D. Chief Financial Honorary Chairman, Holdings Corp. and Chief Business Officer (CFO) Frontage Holdings SVP,

Slide 8: United States Based Services
United States Based Services DMPK SAFETY & BIOANALYTICAL CMC CLINICAL BIOMETRICS TOXICOLOGY • Rapid PK; In Vitro • IND Enabling Studies • Biomarker Services • Analytical Services • Clinical Centers in US • CDISC-Compliant Datasets ADME • Regulatory/general • Preclinical and Clinical • Formulation an

Slide 9: China Based Services
China Based Services Bioanalytical CMC/CTM Clinical • >50,000 sqf facilities • >30,000 sqf facilities • 18 Hospital-based early located in Shanghai and located in Suzhou phase clinical centers in Suzhou different regions • >70 Scientists; >70% • >150 Scientists; >70% have advanced degrees • >1,000 b

Slide 10: State of the Art Equipment and Facilities
State of the Art Equipment and Facilities • ~100 LC-MS/MS available for small and large molecule analysis • Frontage was first to offer ultra-sensitive biomarker quantification with Quanterix SimoaTM • Magpix Luminex and Ella Protein Simple instrument platforms enables efficient screening of multipl

Slide 11: Unparalleled Compliance and Quality Record
Unparalleled Compliance and Quality Record Frontage US FDA Inspections (2000-2018) Service Area (Location) # Inspections Inspection • Our facilities and processes undergo Year/s routine audits and inspections from sponsors and regulatory authorities, BIO-US/ CMC-US (HQ, Exton, PA) 12/2 2004-2018 inc

Slide 12: Other Regulatory Inspections (2000-2018)
1 2 Other Regulatory Inspections (2000-2018) # of Inspection Agency Service Area (Location) Inspection/s Year/s ANVISA (Brazil) BIO-US (HQ Exton, PA) 1 2018 DEA BIO-DMPK-US (HQ Exton, PA) 1 2014 Drug Safety and Metabolism (DSM) DEA 3 2016-2018 (Concord, OH) DEA CMC-US (Exton, PA) 1 2016 DEA FCS (Sec

Slide 13: Drug Discovery and Development Service Overview
Biometrics Clinical CMC DMPK Bioanalytical Safety & Toxicology Drug Discovery and Development Service Overview 13

Slide 14: DMPK
DMPK Technical Expertise • 25+ employees; cross-trained • Avg experience 10-15 years • Ability to provide scientific input to designs and interpretation of data to influence decision- making process Automation for Increased Precision and Efficiency • Advanced automation instrumentation for in vivo A

Slide 15: Safety & Toxicology
Safety & Toxicology Specialized Facilities • Compliance with GLP regulations • AAALAC accreditation • DEA licensed facility, regular inspections with all major regulatory bodies, excellent regulatory track record and reputation • 43 animal rooms • Provantis (wireless data collection, 21 CFR 11 compl

Slide 16: Bioanalytical Services
Bioanalytical Services 17 Years of Strong Scientific Expertise • 70% of staff have advanced degrees • Senior scientists average 10 – 15 years in complex drug development • Many come from leading pharmaceutical companies • Small molecule, biologics and biomarkers expertise Outstanding Quality and Com

Slide 17: CMC (Chemistry, Manufacturing and Control) Services
CMC (Chemistry, Manufacturing and Control) Services Capacity & Expertise • Over 1,500 Methods Method Dev/Method Validation/Method Transfer • 220 Clients -- 220 Compounds -- >450 GMP Batches Outstanding Quality and Compliance • Our facilities and processes undergo routine audits and inspections from

Slide 18: Clinical Services
Clinical Services Over 20 years of Early Stage Clinical Experience • Experience in execution of comprehensive Phase I-IIa studies • Experience in broad range of study types • Expertise in wide variety of delivery systems Purpose-Built Facility • Modern 36,000 sq. ft. facility • Multiple units with 1

Slide 19: Biometrics
Biometrics Extensive Experience • Biostatistics consultation and analyses by staff statisticians with more than 20 years of industry experience • Expertise in generation of CDISC-compliant datasets and supporting documents • Phase I-III and post-marketing study support Broad Service Offerings • Clin

Slide 20: Thank You
Thank You 20

Slide 21: Appendix
—— ~6=§Ei‘<‘<—ti~ AD Appendix

Slide 22: Our Strengths and Growth Strategies
Our Strengths and Growth Strategies Our Strengths Our Growth Strategies 1 1 Well positioned in the world’s two largest Expand Capacities to Capture Market Growth pharmaceutical markets 2 Proven ability to deliver value-add technical 2 expertise Expand Services to Provide Integrated Solutions 3 Effec
Source: Internet Archive copy of frontagelab.com





